Analyst Ratings for Checkmate Pharmaceuticals (CMPI)

CMPI Rating Summary

  |   Expand Research on CMPI
Overall Rating: BUY   Rating Trend: =   Avg. $ Target: N/A
Rating Score: 7.5 / 10   Percentile Rank: 80%
Date Firm Analyst Type Rating
(Past)		 PT
(Past)		 Start $
(End $)		 % Chg. Details
4/20/2022 BTIG Kaveri Pohlman Downgrade Neutral
(Buy)		 N/A
(N/A)		 10.35
(10.50)		 1.45% Details
10/6/2021 BofA Securities
» Updated 3/31/2022		 Geoff Meacham Upgrade Buy
(Neutral)		 6.00
(7.00)		 3.86
(10.50)		 172.02% Details